Blood test-guided chemotherapy after liver tumor removal
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial uses a blood test (ctDNA, a sign of cancer cells shedding into the blood) to help guide chemotherapy after surgery to remove colorectal liver metastases. It may help patients get the right chemotherapy plan after their operation, potentially based on whether cancer material is still detectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are having an elective surgery to remove colorectal cancer that has spread to the liver, with the goal of cure.
- Your colon cancer was already removed or will be removed during the same surgery, not left behind.
- You finished pre-surgery chemotherapy (at least 4 treatment cycles).
- You can and are willing to provide blood samples for the ctDNA blood test.
- You are not currently pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether giving chemotherapy after surgery only for people whose blood test (ctDNA) shows no remaining cancer can help prevent the cancer from coming back. It is for people with colon cancer that has spread to the liver who had the tumor fully removed.
This Phase 3 trial tests whether an added “maintenance” treatment after liver surgery can help prevent colorectal cancer from coming back. It is only for people whose blood test (ctDNA) still shows signs of cancer after their operation.
This study uses a simple blood test (liquid biopsy) to look for tiny bits of cancer DNA after surgery for colorectal cancer that spread to the liver. It aims to see if this test can find cancer earlier than standard scans, which may help guide future treatment decisions.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This study uses a blood test called ctDNA to help tailor (personalize) neoadjuvant chemotherapy for people with colorectal or appendix cancer before surgery. The goal is to see if using ctDNA can help doctors pick the most appropriate chemotherapy plan for you.
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
Hear when a new Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.